Clinical trials of riluzole in patients with ALS
Clinical trials of riluzole in patients with ALS
复制标题
DOI：
10.1212/wnl.47.4_suppl_2.86s
复制
发表时间：
1996-10-01
期刊：
影响因子：
9.9
通讯作者：
Casey, P
中科院分区：
文献类型：
--
作者：
Miller, RG;Bouchard, JP;Casey, P
利鲁唑的两项双盲、安慰剂对照临床试验目前已在1100多名ALS患者中进行。两项研究的结果都显示了在延长生存期方面的适度益处，这在统计学上是显著的。这些结果导致美国食品和药物管理局于1996年初开始在美国使用这种药物。这是第一种治疗渐冻症的药物。它开启了基础和临床研究的新时代，试图找到治疗这种疾病的方法。
Two double-blinded, placebo-controlled clinical trials of riluzole have now been carried out in more than 1,100 patients with ALS. The results of both studies show a modest benefit in prolonging survival that is statistically significant. These results led to the availability of this drug by the Food and Drug Administration for use in the United States beginning in early 1996. This is the first drug that has been available for ALS. It begins a new era in both basic and clinical research in an attempt to find a cure for this disease.